Maraviroc

also known as MVC · UK-427,857 · Selzentry · Celsentri · Maraviroc(Selzentry) · Maraviroc = Celsentri · Rel-maraviroc

Other / unclassified targets CCR5 via inhibition

Developed for: HIV infectious disease · AIDS · COVID-19 · graft versus host disease · cognitive disorder · stroke disorder · AIDS dementia complex · atherosclerosis
+21 more
· coinfection · colorectal cancer · disease related to transplantation · fatty liver disease · hematopoietic and lymphoid cell neoplasm · hypertriglyceridemia · immune reconstitution inflammatory syndrome · Kaposi's sarcoma · kidney disorder · long COVID-19 · malignant pancreatic neoplasm · metastatic malignant neoplasm in the colon · myositis disease · post-viral disorder · pulmonary sarcoidosis · rheumatoid arthritis · viral infectious disease · chronic hepatitis C virus infection · hepatitis B virus infection · hepatitis C virus infection · ischemic stroke
Investigated by: Pfizer · ViiV Healthcare · National Institute of Allergy and Infectious Diseases (NIAID) · Merck Sharp & Dohme LLC · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
+110 more
· GlaxoSmithKline · Abbott · Hospital Clinic of Barcelona · Imperial College London · International Partnership for Microbicides, Inc. · University of California, Los Angeles · University of California, San Francisco · University of Maryland, Baltimore · University of North Carolina, Chapel Hill · ANRS, Emerging Infectious Diseases · Aaron Diamond AIDS Research Center · Abramson Cancer Center at Penn Medicine · Case Western Reserve University · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Federal University of São Paulo · Fight AIDS and Infectious Diseases Foundation · Germans Trias i Pujol Hospital · Gilead Sciences · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Medical Sciences and Nutrition Salvador Zubiran · National Institutes of Health (NIH) · Objectif Recherche Vaccins SIDA · Rockefeller University · St Stephens Aids Trust · University Hospital Heidelberg · University of California, San Diego · University of Hawaii · ASST Fatebenefratelli Sacco · Affiliated Hospital to Academy of Military Medical Sciences · Andalusian Public Foundation for Health Research in Seville · Association Pour la Recherche en Infectiologie · Auritec Pharmaceuticals · Blood and Marrow Transplant Clinical Trials Network · Bruce Brew · CCINSHAE. Secretaría de Salud. México · California HIV/AIDS Research Program · Catholic University of the Sacred Heart · Center for Research in Infectious Diseases · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Children's Hospital Medical Center, Cincinnati · Chinese University of Hong Kong · Cooper Human Systems · Cytheris SA · Dalhousie University · David Garcia Cinca · Emory University · French National Agency for Research on AIDS and Viral Hepatitis · Fundacion Clinic per a la Recerca Biomédica · Fundación Huésped · German Cancer Research Center · Giovanni Di Perri · Guy's and St Thomas' NHS Foundation Trust · HIV Prevention Trials Network · Hospital General de México Dr. Eduardo Liceaga · Hospital Universitario Infanta Leonor · Icahn School of Medicine at Mount Sinai · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Janssen-Cilag Ltd. · Johns Hopkins University · Maple Leaf Research · McGill University Health Centre/Research Institute of the McGill University Health Centre · Medical Research Council · Memorial University of Newfoundland · National Cancer Institute (NCI) · National Institute of Mental Health (NIMH) · Northwestern University · Oak Crest Institute of Science · Ottawa Hospital Research Institute · Parkwood Hospital, London, Ontario · PolyBio Research Foundation · Rhode Island Hospital · Riverview Health Centre Foundation · Robert L. Murphy · all 116 on the full record

Regulatory milestones approvals, filings & regulatory actions · 7 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (5)	US (FDA)	SELZENTRY	—	2008-11-25 – 2020-10-30	fda.gov ↗
Approved	EU (EMA)	Celsentri	—	2007-09-18	europa.eu ↗
Approved	US (FDA)	SELZENTRY	—	2007-08-06	fda.gov ↗

Trials 117 · started per year

today

US approved 2007

EU approved 2007

20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT02431273	Jun 2015 → Dec 2016	—	Auritec Pharmaceuticals	Completed	No outcome recorded
Phase 0	NCT02486510	Jul 2012 → Dec 2015	HIV infectious disease	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Terminated	No outcome recorded
Phase 125 trials
Phase 1	NCT04435522	Oct → Dec 2020	COVID-19	Rhode Island Hospital	Completed	No outcome recorded
Phase 1	NCT03274804	Apr 2018 → Mar 2020	colorectal cancer	University Hospital Heidelberg	Completed	No outcome recorded
Phase 1	NCT02778204	Jun 2017 → Sep 2019	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT04721301	Jan 2017 → Mar 2023	malignant pancreatic neoplasm, metastatic malignant neoplasm in the colon	University Hospital Heidelberg	Completed	No outcome recorded
Phase 1	NCT02625207	Nov 2015 → Mar 2016	—	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT02480894	Jul → Sep 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT02346084	Jan → Dec 2015	HIV infectious disease	International Partnership for Microbicides, Inc.	Completed	No outcome recorded
Phase 1	NCT02039323	Feb → Apr 2014	—	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT01894776	Jun → Dec 2013	HIV infectious disease, Mycobacterium avium complex disease	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 1	NCT01980329	Jan 2013 → Mar 2014	Taqi polymorphism	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT01719627	Oct 2012 → May 2014	HIV infectious disease	Fight AIDS and Infectious Diseases Foundation	Completed	No outcome recorded
Phase 1	NCT01627717	Jun 2012 → Apr 2013	—	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 1	NCT01363037	Nov 2011 → Aug 2012	HIV infectious disease	International Partnership for Microbicides, Inc.	Completed	No outcome recorded
Phase 1	NCT01348763	Oct 2011 → Feb 2012	HIV infectious disease	Imperial College London	Completed	No outcome recorded
Phase 1	NCT01290211	Apr → Jun 2011	—	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT01242579	Jan → Jul 2011	HIV infectious disease	International Partnership for Microbicides, Inc.	Withdrawn	No outcome recorded
Phase 1	NCT01133210	Jan 2011 → Aug 2012	hypertriglyceridemia	Washington University School of Medicine	Completed	No outcome recorded
Phase 1	NCT01140412	Jul → Oct 2010	—	ViiV Healthcare	Terminated	No outcome recorded
Phase 1	NCT01056874	Mar → Apr 2010	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT00982878	Sep 2009 → Jul 2010	HIV infectious disease	Imperial College London	Completed	No outcome recorded
Phase 1	NCT00821535	Feb → May 2009	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT00783484	Oct 2008 → May 2009	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT00775294	May 2008 → May 2009	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT00703586	Sep 2007 → May 2011	HIV infectious disease	Rockefeller University	Completed	No outcome recorded
Phase 1	NCT00496782	Jul 2007 → Oct 2008	HIV infectious disease	ViiV Healthcare	Terminated	No outcome recorded

Phase 1/23 trials
Phase 1/2	NCT02475915	Jan → Nov 2015	—	SEARCH Research Foundation	Completed	No outcome recorded
Phase 1/2	NCT02167451	Jul 2014 → Sep 2018	graft versus host disease	Children's Hospital Medical Center, Cincinnati	Terminated	No outcome recorded
Phase 1/2	NCT00948753	Jun 2009 → Apr 2011	graft versus host disease	Abramson Cancer Center at Penn Medicine	Completed	No outcome recorded
Phase 229 trials
Phase 2	NCT06805656	Jul 2026 → Jan 2027 expected	HIV infectious disease	Federal University of São Paulo	Not yet recruiting	No outcome recorded
Phase 2	NCT06853223	Dec 2025 → Apr 2028 expected	acute lung injury, disease related to transplantation	University of California, San Francisco	Recruiting	No outcome recorded
Phase 2	NCT06640192	May 2025 → Dec 2026 expected	HIV infectious disease	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Recruiting	No outcome recorded
Phase 2	NCT06511063	Oct 2024 → Nov 2026 expected	long COVID-19	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 2	NCT04789616	Sep 2022 → Dec 2025 overdue	stroke disorder	University of Calgary	Recruiting	No outcome recorded
Phase 2	NCT04475991	Jul 2021 → Mar 2022	COVID-19	Hospital General de México Dr. Eduardo Liceaga	Terminated	No outcome recorded
Phase 2	NCT04710199	Feb → Jul 2021	viral infectious disease	Andalusian Public Foundation for Health Research in Seville	Completed	No outcome recorded
Phase 2	NCT05932550	Aug 2020 → Aug 2022	—	Tel-Aviv Sourasky Medical Center	Completed	No outcome recorded
Phase 2	NCT04441385	Jun 2020 → Feb 2021	COVID-19	Hospital Universitario Infanta Leonor	Terminated	No outcome recorded
Phase 2	NCT02741323	Jan 2017 → May 2022	HIV infectious disease, kidney disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02208037	Aug 2014 → Oct 2017	Hodgkins lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, diffuse large B-cell lymphoma +2	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT02799888	Apr 2014 → Dec 2016	graft versus host disease	Affiliated Hospital to Academy of Military Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT01785810	Feb 2013 → Nov 2016	hematopoietic and lymphoid cell neoplasm	Abramson Cancer Center at Penn Medicine	Completed	No outcome recorded
Phase 2	NCT01505114	Jun 2012 → Nov 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT01400412	Jan 2012 → Jun 2014	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 2	NCT01420523	Dec 2011 → Apr 2013	HIV infectious disease, localized lipodystrophy	ANRS, Emerging Infectious Diseases	Terminated	No outcome recorded
Phase 2	NCT01291459	Sep 2011 → Dec 2015	HIV infectious disease	Association Pour la Recherche en Infectiologie	Unknown	No outcome recorded
Phase 2	NCT01276236	Mar 2011 → Jan 2015	Kaposi's sarcoma	University of California, San Francisco	Completed	No outcome recorded
Phase 2	NCT01019551	Sep 2010 → Jul 2012	HIV infectious disease	Objectif Recherche Vaccins SIDA	Completed	No outcome recorded
Phase 2	NCT00993148	May 2010 → Apr 2013	HIV infectious disease	Northwestern University	Completed	No outcome recorded
Phase 2	NCT00987948	Jan 2010 → Nov 2012	HIV infectious disease	University of Hawaii	Completed	No outcome recorded
Phase 2	NCT00976404	Nov 2009 → Jul 2013	HIV infectious disease	Robert L. Murphy	Completed	No outcome recorded
Phase 2	NCT00944541	Sep 2009 → Aug 2010	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 2	NCT00791700	Apr 2009 → Apr 2015	HIV infectious disease	ViiV Healthcare	Unknown	No outcome recorded
Phase 2	NCT00827112	Mar 2009 → Jul 2010	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT00795444	Mar 2008 → Jan 2015	—	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Completed	No outcome recorded
Phase 2	NCT00427934	Feb 2007 → Oct 2008	rheumatoid arthritis	Pfizer	Terminated	No outcome recorded
Phase 2	NCT00634959	Jul → Dec 2003	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT00643643	Oct 2002 → Jun 2003	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded

Phase 2/37 trials
Phase 2/3	NCT03172026	Aug 2019 → Oct 2020	stroke disorder	University of California, Los Angeles	Terminated	No outcome recorded
Phase 2/3	NCT03129113	Mar 2017 → Nov 2020	HIV infectious disease, fatty liver disease	University College, London	Completed	No outcome recorded
Phase 2/3	NCT02159027	Jun 2015 → Feb 2019	AIDS dementia complex	University of Hawaii	Completed	No outcome recorded
Phase 2/3	NCT01154673	Nov 2011 → Sep 2014	—	University of Toronto	Completed	No outcome recorded
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	No outcome recorded
Phase 2/3	NCT00098306	Nov 2004 → Apr 2007	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2/3	NCT00098748	Nov 2004 → Dec 2005	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 313 trials
Phase 3	NCT02588820	Apr 2016 → Nov 2018	HIV infectious disease	David Garcia Cinca	Unknown	No outcome recorded
Phase 3	NCT03708861	Jan 2016 → Dec 2017	HIV infectious disease	University of Turin, Italy	Withdrawn	No outcome recorded
Phase 3	NCT03178084	Oct 2014 → Nov 2016	HIV infectious disease	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Completed	No outcome recorded
Phase 3	NCT01896921	Sep 2013 → Dec 2018	HIV infectious disease	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 3	NCT01345630	Sep 2011 → Aug 2013	—	ViiV Healthcare	Terminated	No outcome recorded
Phase 3	NCT00935480	Oct → Nov 2010	HIV infectious disease	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Completed	No outcome recorded
Phase 3	NCT01033760	Apr 2010 → Jul 2013	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT00808002	Feb 2009 → Nov 2011	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 3	NCT00719823	Aug 2008 → May 2010	HIV infectious disease	ViiV Healthcare	Withdrawn	No outcome recorded
Phase 3	NCT00537394	Jan 2008 → May 2012	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00478231	Jul 2007 → Aug 2010	AIDS	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00426660	Feb 2007 → Jun 2010	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00098293	Nov 2004 → Apr 2007	—	ViiV Healthcare	Completed	No outcome recorded

Phase 427 trials
Phase 4	NCT07668505	Sep 2026 → Aug 2029 expected	myositis disease	Chinese University of Hong Kong	Not yet recruiting	No outcome recorded
Phase 4	NCT04965662	Jan 2018 → Mar 2021	HIV infectious disease	Guy's and St Thomas' NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT03218592	Jun 2017 → Dec 2018	AIDS	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 4	NCT03163277	May 2017 → Jun 2020	HIV infectious disease, cognitive disorder	Giovanni Di Perri	Terminated	No outcome recorded
Phase 4	NCT02990312	May 2017 → Jul 2019	HIV infectious disease	University of Maryland, Baltimore	Withdrawn	No outcome recorded
Phase 4	NCT02519777	Apr 2016 → Dec 2019	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT03402815	Jan 2015 → Apr 2017	HIV infectious disease, atherosclerosis	University Of Perugia	Completed	No outcome recorded
Phase 4	NCT01367236	Jan 2013 → Oct 2015	HIV infectious disease, cognitive disorder	Imperial College London	Completed	No outcome recorded
Phase 4	NCT01866267	Jan → Dec 2013	AIDS	St. Hope Foundation	Completed	No outcome recorded
Phase 4	NCT01680536	Nov 2012 → Nov 2015	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 4	NCT01533272	Feb 2012 → Jun 2014	HIV infectious disease	Hospital Clinic of Barcelona	Completed	No outcome recorded
Phase 4	NCT01449006	Oct 2011 → Sep 2014	HIV infectious disease, post-viral disorder	Bruce Brew	Completed	No outcome recorded
Phase 4	NCT01275625	Jun 2011 → Oct 2012	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT01378910	Jun 2011 → Apr 2014	HIV infectious disease	Fight AIDS and Infectious Diseases Foundation	Completed	No outcome recorded
Phase 4	NCT01367210	Jun 2011 → Jun 2015	HIV infectious disease	Catholic University of the Sacred Heart	Terminated	No outcome recorded
Phase 4	NCT01327547	May 2011 → Apr 2013	coinfection	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT01068873	Apr → Dec 2010	HIV infectious disease	Temple University	Terminated	No outcome recorded
Phase 4	NCT01013987	Feb 2010 → ?	AIDS	Fundación Huésped	Unknown	No outcome recorded
Phase 4	NCT01190293	Jan 2010 → Mar 2012	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 4	NCT00981318	Dec 2009 → May 2015	AIDS	Rodwick, Barry M., M.D.	Terminated	No outcome recorded
Phase 4	NCT00966329	Oct 2009 → May 2012	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 4	NCT00884858	Apr 2009 → Apr 2011	HIV infectious disease	ASST Fatebenefratelli Sacco	Completed	No outcome recorded
Phase 4	NCT00925756	Oct 2008 → May 2012	HIV infectious disease	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT00735072	Sep 2008 → Apr 2010	HIV infectious disease	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT00717067	Jul → Nov 2008	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT00666705	Feb → Mar 2008	—	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT01235013	—	HIV infectious disease	Hospital Clinic of Barcelona	Unknown	No outcome recorded

Phase not applicable8 trials
—	NCT02961829	Jul 2015 → Mar 2019	HIV infectious disease	Federal University of São Paulo	Completed	No outcome recorded
—	NCT02333045	Jan 2015 → Oct 2016	HIV infectious disease	Emory University	Terminated	No outcome recorded
—	NCT02134717	Jan 2014 → May 2015	pulmonary sarcoidosis	University of Pittsburgh	Terminated	No outcome recorded
—	NCT02934022	Jun 2012 → Dec 2014	HIV infectious disease	Southern California Institute for Research and Education	Completed	No outcome recorded
—	NCT01204905	Sep 2010 → May 2014	HIV infectious disease	University of Maryland, Baltimore	Completed	No outcome recorded
—	NCT00988780	Dec 2009 → Mar 2013	HIV infectious disease, immune reconstitution inflammatory syndrome	National Institute of Medical Sciences and Nutrition Salvador Zubiran	Unknown	No outcome recorded
—	NCT00709111	Jan → Oct 2009	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
—	NCT00525733	Oct 2007 → Dec 2013	HIV infectious disease	Rockefeller University	Completed	No outcome recorded
Phase not stated3 trials
—	NCT00801515	Aug 2009 → Jul 2011	HIV infectious disease	ViiV Healthcare	No longer available	No outcome recorded
—	NCT00992654	—	HIV infectious disease	ViiV Healthcare	No longer available	No outcome recorded
—	NCT01776996	—	HIV infectious disease	ViiV Healthcare	No longer available	No outcome recorded

Also used as a comparator or background therapy in 27 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT03060447 Background	May 2017 → Feb 2020	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 1	NCT01749566 Comparator	Dec 2012 → May 2015	HIV infectious disease	Emory University	Completed	No outcome recorded
Phase 1	NCT01597895 Comparator	Jul → Aug 2012	—	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT00771823 Comparator	May → Nov 2008	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 23 trials
Phase 2	NCT07080567 Comparator	Jul 2025 → Dec 2027 expected	ischemic stroke	Emmanuel Carrera	Recruiting	No outcome recorded
Phase 2	NCT04966429 Comparator	May 2021 → Apr 2024	cognitive disorder	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 2	NCT00764465 Comparator	Oct → Dec 2008	—	Garden State Infectious Disease Associates, PA	Completed	No outcome recorded
Phase 2/32 trials
Phase 2/3	NCT06974084 Comparator	Jul → Dec 2026 expected	long COVID-19	HealthBio, Inc.	Not yet recruiting	No outcome recorded
Phase 2/3	NCT00098722 Comparator	Dec 2004 → Apr 2007	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 38 trials
Phase 3	NCT03631732 Comparator	Aug 2018 → Aug 2019	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02469246 Background	Jun 2015 → Dec 2017	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02302547 Comparator	Dec 2014 → Aug 2017	HIV infectious disease	University Hospital, Tours	Completed	No outcome recorded
Phase 3	NCT02121795 Background	May 2014 → Aug 2015	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01348308 Comparator	Sep 2011 → Mar 2016	AIDS	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT00844519 Comparator	Jan 2010 → Dec 2012	HIV infectious disease, cardiovascular disorder	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00708162 Background	Jul 2008 → Dec 2010	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00440271 Background	Feb 2007 → Oct 2008	HIV infectious disease	Boehringer Ingelheim	Terminated	No outcome recorded

Phase 410 trials
Phase 4	NCT02881762 Comparator	Jun 2017 → Mar 2019	HIV infectious disease, hepatitis C virus infection	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT01637259 Comparator	Jun 2012 → Dec 2015	HIV infectious disease, proteinuria	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT01389063 Comparator	Jan 2012 → Sep 2014	—	S.F.L. van Lelyveld	Unknown	No outcome recorded
Phase 4	NCT01384682 Comparator	Aug 2011 → Dec 2015	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00981773 Comparator	Sep 2009 → Mar 2013	HIV infectious disease	Imperial College London	Terminated	No outcome recorded
Phase 4	NCT01049204 Comparator	Jul 2009 → Jun 2011	HIV infectious disease	St Stephens Aids Trust	Terminated	No outcome recorded
Phase 4	NCT00870363 Comparator	Apr 2009 → Apr 2013	HIV infectious disease	University of California, Davis	Completed	No outcome recorded
Phase 4	NCT00782301 Comparator	Mar 2009 → Feb 2010	HIV infectious disease, chronic hepatitis C virus infection, hepatitis B virus infection	ViiV Healthcare	Withdrawn	No outcome recorded
Phase 4	NCT00875368 Comparator	Feb 2009 → Dec 2011	HIV infectious disease	S.F.L. van Lelyveld	Completed	No outcome recorded
Phase 4	NCT00853840 Comparator	Apr → May 2008	AIDS	ViiV Healthcare	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2014-07-22	Pfizer	ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1 pfizer.com ↗

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 148 sources stand behind the page.

Field	Value	Cited text
Known as	Maraviroc	“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ 142 “The three antiretroviral drugs have been chosen because they are the only ones that allow administration at higher doses without causing increased toxicity: dolutegravir 50...” NCT06640192 ↗ “This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive...” NCT01776996 ↗ “Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks” NCT01019551 ↗ “The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.” NCT03060447 ↗ “We randomly assigned for 48 weeks 22 patients to continue their current first line regimen of Truvada® plus Kaletra® or intensify it with Maraviroc and Raltegravir.” PMID 25320633 ↗ Oct 2014 “A triple combination IVR building on this platform and delivering TDF-FTC along with the antiretroviral (ARV) agent maraviroc (MVC) also is under development.” PMID 30265679 ↗ Sep 2018 “Maraviroc inhibits CCR5-tropic HIV-1 across different subtypes in vitro and has demonstrated efficacy in clinical trials.” PMID 34160290 ↗ Jan 2021 “efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP)” NCT02469246 ↗ “Tenofovir+Emtricitabine+Third agent (Including a fusion inhibitor: enfuvirtide or a CCR5 antagonist :maraviroc” NCT02302547 ↗ “As of today, maraviroc is the only CCR5-antagonist approved for HIV treatment.” NCT01378910 ↗ “etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF)” NCT00708162 ↗ “6. Maraviroc 150 mg twice a day” NCT02588820 ↗ “maraviroc (MVC; Selzentry®)” NCT02121795 ↗ “maraviroc 150 mg once daily” NCT01367236 ↗ “maraviroc (MVC)” NCT03631732 ↗ “Maraviroc,” NCT00440271 ↗ NCT01056874 ↗ NCT00981318 ↗ NCT06974084 ↗ NCT04721301 ↗ NCT01348308 ↗ NCT02208037 ↗ NCT01680536 ↗ NCT01597895 ↗ NCT02167451 ↗ NCT01719627 ↗ NCT00098722 ↗ NCT01068873 ↗ NCT00719823 ↗ NCT02741323 ↗ NCT02159027 ↗ NCT02039323 ↗ NCT01785810 ↗ NCT00771823 ↗ NCT00948753 ↗ NCT00801515 ↗ NCT03274804 ↗ NCT01894776 ↗ NCT02480894 ↗ NCT02519777 ↗ NCT02961829 ↗ NCT01235013 ↗ NCT01627717 ↗ NCT00098306 ↗ NCT03178084 ↗ NCT01276236 ↗ NCT01980329 ↗ NCT00098748 ↗ NCT02475915 ↗ NCT01420523 ↗ NCT01133210 ↗ NCT07668505 ↗ NCT00808002 ↗ NCT02990312 ↗ NCT02486510 ↗ NCT00992654 ↗ NCT01140412 ↗ NCT00426660 ↗ NCT00717067 ↗ NCT00783484 ↗ NCT01154673 ↗ NCT00875368 ↗ NCT00782301 ↗ NCT00427934 ↗ NCT01033760 ↗ NCT01384682 ↗ NCT00976404 ↗ NCT04966429 ↗ NCT00709111 ↗ NCT01204905 ↗ NCT00966329 ↗ NCT00478231 ↗ NCT00827112 ↗ NCT01327547 ↗ NCT04710199 ↗ NCT00944541 ↗ NCT00988780 ↗ NCT02346084 ↗ NCT01637259 ↗ NCT00981773 ↗ NCT02881762 ↗ NCT00791700 ↗ NCT00870363 ↗ NCT00666705 ↗ NCT00775294 ↗ NCT03708861 ↗ NCT01049204 ↗ NCT00982878 ↗ NCT03163277 ↗ NCT01896921 ↗ NCT07080567 ↗ NCT03218592 ↗ NCT02333045 ↗ NCT01242579 ↗ NCT00987948 ↗ NCT00643643 ↗ NCT01505114 ↗ NCT00496782 ↗ NCT03402815 ↗ NCT06805656 ↗ NCT01749566 ↗ NCT01013987 ↗ NCT00735072 ↗ NCT01291459 ↗ NCT01400412 ↗ NCT04441385 ↗ NCT00925756 ↗ NCT00821535 ↗ NCT00884858 ↗ NCT01866267 ↗ NCT01533272 ↗ NCT04789616 ↗ NCT00703586 ↗ NCT00537394 ↗ NCT06853223 ↗ NCT00098293 ↗ NCT03129113 ↗ NCT01449006 ↗ NCT01190293 ↗ NCT04475991 ↗ NCT00764465 ↗ NCT01345630 ↗ NCT00795444 ↗ NCT02625207 ↗ NCT01389063 ↗ NCT04435522 ↗ NCT00525733 ↗ NCT00853840 ↗ NCT02934022 ↗ NCT01290211 ↗ NCT02778204 ↗ NCT01348763 ↗ NCT02134717 ↗ NCT02799888 ↗ NCT05932550 ↗ NCT03172026 ↗ NCT04965662 ↗ NCT01367210 ↗ NCT00844519 ↗ NCT00993148 ↗ NCT01363037 ↗ NCT00634959 ↗
Known as	Celsentri	“Maraviroc brand name in the EC is Celsentri.” NCT00884858 ↗ 3 “maraviroc (Celsentri®): 150 mg bid.” NCT01033760 ↗ “maraviroc (Selzentry, Celsentri)” NCT07668505 ↗ “Maraviroc (Celsentri)” NCT01348308 ↗
Known as	Maraviroc = Celsentri	“Maraviroc = Celsentri” NCT01190293 ↗
Known as	Maraviroc(Selzentry)	“Maraviroc (Selzentry)” NCT01068873 ↗ 1 “Maraviroc(Selzentry)” NCT01204905 ↗
Known as	MVC	“The primary objective was to assess the effect of MVC intensification on latently infected CD4(+) T cells in chronically HIV-1-infected patients receiving antiretroviral...” PMID 22174752 ↗ Dec 2011 16 “A strategy to modulate activation and trafficking of leukocytes to the lungs is by blocking CCR5 by using maraviroc (MVC), which has shown capable of modulating conditions of...” NCT04475991 ↗ “A single arm, open-labeled trial was conducted to examine the effect of maraviroc (MVC) intensification on monocyte inflammation and neuropsychological (NP) performance in 15...” PMID 25227930 ↗ Sep 2014 “Maraviroc (MVC) is a member of a new class of antiretroviral compounds known as small molecule CCR5 antagonists that block R5 HIV entry into cluster of differentiation 4 (CD4) cells.” NCT01276236 ↗ “A triple combination IVR building on this platform and delivering TDF-FTC along with the antiretroviral (ARV) agent maraviroc (MVC) also is under development.” PMID 30265679 ↗ Sep 2018 “Maraviroc (MVC) is a CCR5 antagonist that prevents virus entry blocking the binding of R5-tropic HIV to the cell surface CCR5 co-receptor.” NCT01190293 ↗ “Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.” PMID 27048747 ↗ Apr 2016 “efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP)” NCT02469246 ↗ “Use of Maraviroc (MVC) in Immunological Non-responder HIV-1-infected Patients.” NCT00884858 ↗ “Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days” NCT02346084 ↗ “Chemokine Receptor 5 (CCR5) Entry Inhibitor Maraviroc (MVC)” NCT00764465 ↗ “using the CCR5 receptor antagonist maraviroc (MVC)” NCT01749566 ↗ “Maraviroc (MVC) is a drug, very well tolerated” NCT04710199 ↗ “Maraviroc (MVC), a CCR5 antagonist” NCT04965662 ↗ “Drug: Maraviroc (MVC)” NCT06974084 ↗ “maraviroc (MVC)” NCT03631732 ↗ “Maraviroc (MVC)” NCT02519777 ↗
Known as	Rel-maraviroc	ChEMBL registry synonym — accepted as the source's own label CHEMBL256907 ↗
Known as	Selzentry	“Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5.” NCT00987948 ↗ 4 “by the CCR5 antagonist drug maraviroc (Selzentry) administered to healthy volunteers” NCT01719627 ↗ “Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days” NCT02346084 ↗ “maraviroc (Selzentry, Celsentri)” NCT07668505 ↗ NCT06511063 ↗
Known as	UK-427,857	“Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).” NCT03178084 ↗ 6 “Maraviroc (UK-427,857), a selective and reversible CCR5 co-receptor antagonist” NCT00098748 ↗ “Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist” NCT00098293 ↗ “Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist” NCT00098306 ↗ “Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist” NCT00098722 ↗ “Maraviroc (UK-427,857)” NCT00634959 ↗ “Maraviroc (UK-427,857)” NCT00643643 ↗
Action	Inhibit	“a selective and reversible CCR5 coreceptor antagonist” NCT00098293 ↗
Modality	Other / unclassified	“Maraviroc is a new ART agent from a novel class of HIV inhibitors, entry inhibitors” NCT00870363 ↗
Route	Oral	“300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.” NCT00427934 ↗
Target	CCR5	“a selective and reversible CCR5 coreceptor antagonist” NCT00098306 ↗